Steady-state concentrations of flucloxacillin in porcine vertebral cancellous bone and intervertebral disc following oral and intravenous administration assessed by microdialysis
- 29 April 2022
- journal article
- research article
- Published by Springer Nature in European Spine Journal
- Vol. 31 (6) , 1508-1514
Abstract
Aims Flucloxacillin is a frequently used antibiotic in the treatment of spondylodiscitis. We assessed steady-state concentrations and time above minimal inhibitory concentration (fT > MIC) of flucloxacillin in the intervertebral disc, vertebral cancellous bone, subcutaneous tissue and plasma, after intravenous and oral administration. Methods Sixteen pigs were randomized into two groups; Group Peroral (Group PO) and Group Intravenous (Group IV) received 1 g flucloxacillin every 6 h for 24 h orally or intravenously. Microdialysis was used for sampling in the compartments of interest. A flucloxacillin target of 50% fT > MIC was applied for three MIC targets: 0.125, 0.5 and 2.0 μg/mL. Results Intravenous administration resulted in significantly longer fT > MIC for all targets. Target attainment was only reached for the low target of 0.125 μg/mL in Group IV in vertebral cancellous bone, subcutaneous tissue, and plasma (intervertebral disc 47%). In Group IV, mean fT > MIC values in the investigated compartments were in the range of 47–67% of the dosing interval for 0.125 μg/mL, 20–35% for 0.5 μg/mL, and 0–15% for 2.0 μg/mL. In Group PO, mean fT > MIC values for 0.125 μg/mL were in the range of 1–33%. No pigs reached a concentration of 0.5 μg/mL in any of the investigated compartments in Group PO. Conclusion Administration of 1 g flucloxacillin every 6 h resulted in surprisingly low steady-state fT > MIC after intravenous and oral administration. However, intravenous administration resulted in significantly higher concentrations across compartments compared to oral administration. Sufficient target tissue concentrations for treatment of spondylodiscitis may require a dose increase or alternative dosing regimens.Keywords
Funding Information
- Novo Nordisk Fonden (NNF18OC0033304)
- Direktør Emil C. Hertz og Hustru Inger Hertz Fond
- Læge Sofus Carl Emil Friis og Hustru Olga Doris Friis' Legat
- Augustinus Fonden (19-0320)
- Aase og Ejnar Danielsens Fond (19-10-0025)
This publication has 28 references indexed in Scilit:
- Spondylodiscitis: update on diagnosis and managementJournal of Antimicrobial Chemotherapy, 2010
- Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokineticsJournal of Antimicrobial Chemotherapy, 2010
- Infectious spondylodiscitisJournal of Infection, 2008
- Population Pharmacokinetics at Two Dose Levels and Pharmacodynamic Profiling of FlucloxacillinAntimicrobial Agents and Chemotherapy, 2007
- Are animal models useful for studying human disc disorders/degeneration?European Spine Journal, 2007
- Histology and Pathology of the Human Intervertebral DiscJournal of Bone and Joint Surgery, 2006
- MicrodialysisClinical Pharmacokinetics, 2005
- Relationship between plasma and bone concentrations of cefuroxime and flucloxacillin three different parenteral administrations compared in 30 arthroplastiesBiopharmaceutics & Drug Disposition, 1994
- Plasma and bone concentrations of cefuroxime and flucloxacillin: Oral versus parenteral administration in 20 arthroplastiesActa Orthopaedica, 1993
- Flucloxacillin, a New Isoxazolyl Penicillin, Compared with Oxacillin, Cloxacillin, and DicloxacillinBMJ, 1970